Patents by Inventor Martha Davidovich
Martha Davidovich has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8513428Abstract: A process is provided for preparing the HIV protease inhibitor atazanavir bisulfate wherein a solution of atazanavir free base is reacted with concentrated sulfuric acid in an amount to react with less than about 15% by weight of the free base, seeds of Form A crystals of atazanavir bisulfate are added to the reaction mixture, and as crystals of the bisulfate form, additional concentrated sulfuric acid is added in multiple stages at increasing rates according to a cubic equation, to effect formation of Form A crystals of atazanavir bisulfate. A process is also provided for preparing atazanavir bisulfate as Pattern C material. A novel form of atazanavir bisulfate is also provided which is Form E3 which is a highly crystalline triethanolate solvate of the bisulfate salt from ethanol.Type: GrantFiled: October 8, 2010Date of Patent: August 20, 2013Assignee: Bristol-Meyers Squibb CompanyInventors: Soojin Kim, Bruce T. Lotz, Mary F. Malley, Jack Z. Gougoutas, Martha Davidovich, Sushil K. Srivastava
-
Publication number: 20110124689Abstract: A process is provided for preparing the HIV protease inhibitor atazanavir bisulfate wherein a solution of atazanavir free base is reacted with concentrated sulfuric acid in an amount to react with less than about 15% by weight of the free base, seeds of Form A crystals of atazanavir bisulfate are added to the reaction mixture, and as crystals of the bisulfate form, additional concentrated sulfuric acid is added in multiple stages at increasing rates according to a cubic equation, to effect formation of Form A crystals of atazanavir bisulfate. A process is also provided for preparing atazanavir bisulfate as Pattern C material. A novel form of atazanavir bisulfate is also provided which is Form E3 which is a highly crystalline triethanolate solvate of the bisulfate salt from ethanol.Type: ApplicationFiled: October 8, 2010Publication date: May 26, 2011Inventors: Soojin Kim, Bruce T. Lotz, Mary F. Malley, Jack Z. Gougoutas, Martha Davidovich, Sushil K. Srivastava
-
Patent number: 7838678Abstract: A process is provided for preparing the HIV protease inhibitor atazanavir bisulfate wherein a solution of atazanavir free base is reacted with concentrated sulfuric acid in an amount to react with less than about 15% by weight of the free base, seeds of Form A crystals of atazanavir bisulfate are added to the reaction mixture, and as crystals of the bisulfate form, additional concentrated sulfuric acid is added in multiple stages at increasing rates according to a cubic equation, to effect formation of Form A crystals of atazanavir bisulfate. A process is also provided for preparing atazanavir bisulfate as Pattern C material. A novel form of atazanavir bisulfate is also provided which is Form E3 which is a highly crystalline triethanolate solvate of the bisulfate salt from ethanol.Type: GrantFiled: January 27, 2009Date of Patent: November 23, 2010Assignee: Bristol-Myers Squibb CompanyInventors: Soojin Kim, Bruce T. Lotz, Mary F. Malley, Jack Z. Gougoutas, Martha Davidovich, Sushil K. Srivastava
-
Patent number: 7829720Abstract: A process is provided for preparing the HIV protease inhibitor atazanavir bisulfate wherein a solution of atazanavir free base is reacted with concentrated sulfuric acid in an amount to react with less than about 15% by weight of the free base, seeds of Form A crystals of atazanavir bisulfate are added to the reaction mixture, and as crystals of the bisulfate form, additional concentrated sulfuric acid is added in multiple stages at increasing rates according to a cubic equation, to effect formation of Form A crystals of atazanavir bisulfate. A process is also provided for preparing atazanavir bisulfate as Pattern C material. A novel form of atazanavir bisulfate is also provided which is Form E3 which is a highly crystalline triethanolate solvate of the bisulfate salt from ethanol.Type: GrantFiled: May 2, 2005Date of Patent: November 9, 2010Assignee: Bristol-Myers Squibb CompanyInventors: Soojin Kim, Bruce T. Lotz, Mary F. Malley, Jack Z. Gougoutas, Martha Davidovich, Sushil K. Srivastava
-
Publication number: 20090203630Abstract: A process is provided for preparing the HIV protease inhibitor atazanavir bisulfate wherein a solution of atazanavir free base is reacted with concentrated sulfuric acid in an amount to react with less than about 15% by weight of the free base, seeds of Form A crystals of atazanavir bisulfate are added to the reaction mixture, and as crystals of the bisulfate form, additional concentrated sulfuric acid is added in multiple stages at increasing rates according to a cubic equation, to effect formation of Form A crystals of atazanavir bisulfate. A process is also provided for preparing atazanavir bisulfate as Pattern C material. A novel form of atazanavir bisulfate is also provided which is Form E3 which is a highly crystalline triethanolate solvate of the bisulfate salt from ethanol.Type: ApplicationFiled: January 27, 2009Publication date: August 13, 2009Inventors: Soojin Kim, Bruce T. Lotz, Mary F. Malley, Jack Z. Gougoutas, Martha Davidovich, Sushil K. Srivastava
-
Patent number: 7153879Abstract: There are provided in accordance with the present invention two crystalline polymorphs, designated Form A and Form B, respectively, as well as mixtures thereof, of an epothilone analog represented by the formula Also provided are methods of forming the novel polymorphs, therapeutic methods utilizing them and pharmaceutical dosage forms containing them.Type: GrantFiled: November 10, 2005Date of Patent: December 26, 2006Assignee: Bristol-Myers Squibb CompanyInventors: John D. DiMarco, Jack Z. Gougoutas, Imre M. Vitez, Martha Davidovich, Michael A. Galella, Timothy M. Malloy, Zhenrong Guo, Denis Favreau
-
Publication number: 20060116420Abstract: The present invention relates to crystalline forms of 3?-tert-Butyl-3?-N-tert-butyloxycarbonyl-4-deacetyl-3 ?-dephenyl-3?-N-debenzoyl-4-O-methoxycarbonyl-paclitaxel represented by formula I; processes for the production thereof; pharmaceutical compositions thereof; methods for preparing the pharmaceutical composition; and methods for inhibiting tumor growth therewith.Type: ApplicationFiled: November 22, 2005Publication date: June 1, 2006Inventors: Ramakrishnan Chidambaram, Robert Perrone, Martha Davidovich, John DiMarco, Gary McGeorge, Imre Vitez
-
Publication number: 20060063815Abstract: There are provided in accordance with the present invention two crystalline polymorphs, designated Form A and Form B, respectively, as well as mixtures thereof, of an epothilone analog represented by the formula Also provided are methods of forming the novel polymorphs, therapeutic methods utilizing them and pharmaceutical dosage forms containing them.Type: ApplicationFiled: November 10, 2005Publication date: March 23, 2006Inventors: John DiMarco, Jack Gougoutas, Imre Vitez, Martha Davidovich, Michael Galella, Timothy Malloy, Zhenrong Guo, Denis Favreau
-
Patent number: 6982276Abstract: There are provided in accordance with the present invention two crystalline polymorphs, designated Form A and Form B, respectively, as well as mixtures thereof, of an epothilone analog represented by the formula Also provided are methods of forming the novel polymorphs, therapeutic methods utilizing them and pharmaceutical dosage forms containing them.Type: GrantFiled: February 6, 2004Date of Patent: January 3, 2006Assignee: Bristol-Myers Squibb CompanyInventors: John D. DiMarco, Jack Z. Gougoutas, Imre M. Vitez, Martha Davidovich, Michael A. Galella, Timothy M. Malloy, Zhenrong Guo, Denis Favreau
-
Publication number: 20050256202Abstract: A process is provided for preparing the HIV protease inhibitor atazanavir bisulfate wherein a solution of atazanavir free base is reacted with concentrated sulfuric acid in an amount to react with less than about 15% by weight of the free base, seeds of Form A crystals of atazanavir bisulfate are added to the reaction mixture, and as crystals of the bisulfate form, additional concentrated sulfuric acid is added in multiple stages at increasing rates according to a cubic equation, to effect formation of Form A crystals of atazanavir bisulfate. A process is also provided for preparing atazanavir bisulfate as Pattern C material. A novel form of atazanavir bisulfate is also provided which is Form E3 which is a highly crystalline triethanolate solvate of the bisulfate salt from ethanol.Type: ApplicationFiled: May 2, 2005Publication date: November 17, 2005Inventors: Soojin Kim, Bruce Lotz, Mary Malley, Jack Gougoutas, Martha Davidovich, Sushil Srivastava
-
Publication number: 20040157897Abstract: There are provided in accordance with the present invention two crystalline polymorphs, designated Form A and Form B, respectively, as well as mixtures thereof, of an epothilone analog represented by the formula 1Type: ApplicationFiled: February 6, 2004Publication date: August 12, 2004Inventors: John D. DiMarco, Jack Z. Gougoutas, Imre M. Vitez, Martha Davidovich, Michael A. Galella, Timothy M. Malloy, Zhenrong Guo, Denis Favreau
-
Patent number: 6689802Abstract: There are provided in accordance with the present invention two crystalline polymorphs, designated Form A and Form B, respectively, as well as mixtures thereof, of an epothilone analog represented by the formula Also provided are methods of forming the novel polymorphs, therapeutic methods utilizing them and pharmaceutical dosage forms containing them.Type: GrantFiled: August 9, 2001Date of Patent: February 10, 2004Assignee: Bristol-Myers Squibb CompanyInventors: John D. DiMarco, Jack Z. Gougoutas, Imre M. Vitez, Martha Davidovich, Michael A. Galella, Timothy M. Malloy, Zhenrong Guo, Denis Favreau
-
Publication number: 20020188014Abstract: There are provided in accordance with the present invention two crystalline polymorphs, designated Form A and Form B, respectively, as well as mixtures thereof, of an epothilone analog represented by the formula 1Type: ApplicationFiled: August 9, 2001Publication date: December 12, 2002Inventors: John D. DiMarco, Jack Z. Gougoutas, Imre M. Vitez, Martha Davidovich, Michael A. Galella, Timothy M. Malloy, Zhenrong Guo, Denis Favreau
-
Patent number: 6413969Abstract: There are provided in accordance with the present invention crystalline gatifloxacin pentahydrate represented by the formula in a highly homogeneous form with respect to other crystalline forms thereof.Type: GrantFiled: August 17, 2001Date of Patent: July 2, 2002Assignee: Bristol-Myers Squibb CompanyInventors: Krishnaswamy S. Raghavan, Sunanda A. Ranadive, Jack Z. Gougoutas, John D. DiMarco, William L. Parker, Martha Davidovich, Ann Newman
-
Publication number: 20020052379Abstract: There are provided in accordance with the present invention crystalline gatifloxacin pentahydrate represented by the formula 1Type: ApplicationFiled: August 17, 2001Publication date: May 2, 2002Inventors: Krishnaswamy S. Raghavan, Sunanda A. Ranadive, Jack Z. Gougoutas, John D. DiMarco, William L. Parker, Martha Davidovich, Ann Newman